Core Viewpoint - Tilray Brands, Inc. will implement a one-for-ten reverse stock split of its common stock, effective December 1, 2025, to align its share structure with similar companies and enhance attractiveness to institutional investors [1][2][3][8]. Summary by Sections Reverse Stock Split Details - The reverse stock split will reduce the number of outstanding shares from approximately 1.16 billion to 116 million, with every ten shares converting into one [3]. - Fractional shares will not be issued; instead, stockholders will receive cash for any fractional shares [3]. - The split-adjusted shares will begin trading under the same symbol (TLRY) on December 2, 2025 [2]. Objectives of the Reverse Stock Split - Aligning the number of shares outstanding with companies of similar size and scope [8]. - Making Tilray more attractive to institutional shareholders [8]. - Reducing expenditures associated with the Annual Meeting of Stockholders, resulting in potential annual cost savings of up to $1 million [8]. Company Overview - Tilray Brands is a global lifestyle and consumer packaged goods company with operations in multiple regions, including Canada, the U.S., Europe, Australia, and Latin America [5]. - The company aims to be a leading premium lifestyle brand with a diverse portfolio of over 40 brands across more than 20 countries, focusing on cannabis, hemp-based foods, and craft beverages [5].

Core Points - Lion Group Holding Ltd. (NASDAQ: LGHL) executed a reverse stock split at a ratio of 13 for 1 on November 26, 2025, aimed at increasing the stock price by reducing the number of shares outstanding [1] - The ratio of American Depositary Shares (ADSs) to Class A ordinary shares will change from 2,500 to 32,500, effectively acting as a one-for-thirteen reverse ADS split for ADS holders [2] - LGHL's current stock price is $0.43, reflecting a 4.71% increase, with a trading range today between $0.39 and $0.44, and significant volatility over the past year with a high of $16.4 and a low of $0.30 [3] - The company's market capitalization is approximately $45.6 million, with a trading volume of 161,207 shares, indicating the company's size and stock liquidity [4]

As filed with the U.S. Securities and Exchange Commission on November 25, 2025. Registration No. 333-290902 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO REGISTRATION STATEMENT ON FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PMGC HOLDINGS INC. (Exact name of registrant as specified in its charter) Nevada 5912 33-2382547 (State or Other Jurisdiction of Incorporation or Organization) (Primary Standard Industrial Classification Code Number) (I.R. ...

As filed with the U.S. Securities and Exchange Commission on November 25, 2025. Registration No. 333-290428 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO REGISTRATION STATEMENT ON FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PMGC HOLDINGS INC. (Exact name of registrant as specified in its charter) Nevada 5912 33-2382547 (State or Other Jurisdiction of Incorporation or Organization) (Primary Standard Industrial Classification Code Number) (I.R. ...

Core Viewpoint - INVO Fertility, Inc. will implement a 1-for-8 reverse stock split effective November 28, 2025, to enhance its stock price and maintain compliance with Nasdaq listing requirements [1][2]. Company Overview - INVO Fertility is a healthcare services company focused on the fertility market, particularly in expanding assisted reproductive technology (ART) care [3]. - The company's strategy includes building, acquiring, and operating fertility clinics, specifically "INVO Centers" that offer the intravaginal culture (IVC) procedure using the proprietary INVOcell medical device [3]. - INVO Fertility currently operates two INVO Centers and one IVF clinic in the United States and distributes the INVOcell technology to third-party fertility clinics [3]. - The IVC procedure is designed to provide a more natural, intimate, and cost-effective alternative to traditional IVF, with comparable results at a lower cost [3].

Core Viewpoint - TEN Holdings, Inc. will implement a 1-for-15 reverse stock split, effective December 1, 2025, with trading on a split-adjusted basis starting December 2, 2025 [1][2][3]. Group 1: Reverse Stock Split Details - The reverse stock split will reduce the number of outstanding shares from approximately 44.8 million to about 3.0 million [3]. - The effective time for the reverse stock split is set for 4:30 p.m. Eastern Time on December 1, 2025 [2]. - No fractional shares will be issued; instead, holders will receive cash payments for any fractional shares [3][4]. Group 2: Company Information - TEN Holdings operates through its subsidiary, Ten Events, Inc., providing event planning, production, and broadcasting services [6]. - The company specializes in virtual, hybrid, and physical events, utilizing its proprietary Xyvid Pro Platform for service delivery [6].

Core Viewpoint - ProMIS Neurosciences Inc. has announced a one-for-twenty-five reverse stock split to comply with Nasdaq listing requirements and aims to increase the market price of its common shares [1][11]. Group 1: Reverse Stock Split Details - The reverse stock split will take effect at 12:01 a.m. Eastern Time on November 28, 2025, with shares trading on a split-adjusted basis from that date [2]. - The number of outstanding common shares will decrease from approximately 53,811,110 shares to about 2,152,444 shares [3]. - Proportional adjustments will be made to equity incentive plans, stock options, and outstanding warrants in accordance with the reverse stock split [4]. Group 2: Compliance with Nasdaq - ProMIS received a deficiency letter from Nasdaq on January 8, 2025, indicating that its common shares had not maintained the minimum required closing bid price of at least $1.00 [8]. - The company was granted an additional 180-day compliance period until December 29, 2025, to regain compliance with the Bid Price Rule [10]. - The reverse stock split is part of the company's strategy to cure the deficiency and meet Nasdaq's listing standards [11]. Group 3: Shareholder Information - No fractional shares will be issued; shareholders entitled to fractional shares will receive cash instead [5]. - Stockholders with shares held in book-entry form or through a bank or broker will see the effects of the reverse stock split reflected in their accounts without needing to take action [6]. Group 4: Company Overview - ProMIS Neurosciences is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative disorders, including Alzheimer's disease [13]. - The company utilizes its proprietary target discovery engine, EpiSelect™, to identify novel targets associated with misfolded proteins [13].

Financial Data and Key Metrics Changes - The company held its 2025 Annual General Meeting, where various proposals were presented for stockholder voting, including a reverse stock split and reincorporation [1][2][3] - The preliminary report indicated that all proposals, including the amendment to the equity incentive plan and the issuance of shares to Streeterville Capital, were approved by a majority of votes [12][13][14][15] Business Line Data and Key Metrics Changes - Specific financial data and performance metrics for individual business lines were not disclosed in the meeting [1][2][3] Market Data and Key Metrics Changes - No specific market data or key metrics were provided during the meeting [1][2][3] Company Strategy and Development Direction - The company proposed a reverse stock split to potentially enhance its stock price and market perception, with a range of 1-for-2 to a maximum of 1-for-10 [9][13] - The reincorporation from Delaware to Nevada was aimed at potentially benefiting from a more favorable regulatory environment [10][13] Management's Comments on Operating Environment and Future Outlook - Management did not provide specific comments on the operating environment or future outlook during the meeting [1][2][3] Other Important Information - The meeting included the election of seven directors, with all nominated candidates successfully elected [12] - The company plans to increase the number of shares authorized for issuance under its equity incentive plan to 5 million [14] Summary of Q&A Session - No Q&A session was documented in the provided meeting records [1][2][3]

Financial Data and Key Metrics Changes - The stockholders approved the proposal to grant discretionary authority to the Board of Directors for a reverse stock split within a range of 1-for-2 to a maximum of 1-for-10, indicating a strategic move to potentially enhance share value [12][13][14] - The company successfully ratified the selection of M&K CPAs as the independent registered public accounting firm for the fiscal year ending December 31, 2025, ensuring compliance and transparency in financial reporting [15] Business Line Data and Key Metrics Changes - The amendment to the 2022 equity incentive plan to increase the number of shares authorized for issuance to 5 million was approved, which may impact employee compensation and retention strategies [14] Market Data and Key Metrics Changes - The approval of the issuance of shares to Streeterville Capital, LLC, in prepaid financing transactions that may collectively equal or exceed 20% of the issued and outstanding shares indicates a significant capital raise strategy [14] Company Strategy and Development Direction - The company is pursuing a reincorporation from Delaware to Nevada, which may provide more favorable business regulations and tax benefits [13] Management's Comments on Operating Environment and Future Outlook - Management did not provide specific comments on the operating environment or future outlook during this meeting, focusing instead on the proposals and voting results Other Important Information - The meeting concluded with the election of seven directors, ensuring continuity in governance and strategic direction [12][13] Summary of Q&A Session - There were no recorded questions or answers during the meeting, as the focus was primarily on the proposals and voting outcomes

Prophase Labs (NasdaqCM:PRPH) Q3 2025 Earnings Call November 19, 2025 02:00 PM ET Company ParticipantsNoella Alexander-Young - Media Relations Coordinator and Virtual Event ModeratorTed Karkus - Chairman and CEONoella Alexander-YoungHello and good afternoon, everyone. Welcome to today's presentation. My name is Noella Alexander-Young, Virtual Event Moderator here at Renmark Financial Communications. On behalf of our team, we want to thank everyone for joining us today for ProPhase Labs' third quarter 2025 r ...